Company Performance - OmniAb, Inc. reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.13 per share a year ago, indicating a surprise of -7.14% [1] - The company posted revenues of $3.9 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 35.71%, and down from $7.61 million in the same quarter last year [2] - Over the last four quarters, OmniAb has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - OmniAb shares have declined approximately 42.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $6.51 million, and for the current fiscal year, it is -$0.59 on revenues of $23.59 million [7] Industry Outlook - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact OmniAb's stock performance [5]

Core Viewpoint - Xencor reported a quarterly loss of $0.66 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.63, but an improvement from a loss of $1.11 per share a year ago [1][2] Financial Performance - The company posted revenues of $32.73 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 48.38% and significantly up from $12.81 million in the same quarter last year [3] - Xencor has surpassed consensus revenue estimates three times over the last four quarters [3] Stock Performance - Xencor shares have declined approximately 63.2% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $18.77 million, and for the current fiscal year, it is -$2.92 on revenues of $81.09 million [8] - The trend of estimate revisions for Xencor is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Drugs industry, to which Xencor belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]